Mesa Laboratories
Market Cap
US$1.1b
Last Updated
2020/02/16 23:42 UTC
Data Sources
Company Financials +
Executive Summary
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in Europe, Africa, Asia, South America, Australia, Canada, and Central America.
Rewards
Risk Analysis
Snowflake Analysis
Reasonable growth potential with mediocre balance sheet.
Similar Companies
Share Price & News
How has Mesa Laboratories's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MLAB has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
-2.4%
MLAB
2.2%
US Medical Equipment
1.5%
US Market
1 Year Return
12.9%
MLAB
22.1%
US Medical Equipment
20.1%
US Market
Return vs Industry: MLAB underperformed the US Medical Equipment industry which returned 22.1% over the past year.
Return vs Market: MLAB underperformed the US Market which returned 20.1% over the past year.
Shareholder returns
| MLAB | Industry | Market | |
|---|---|---|---|
| 7 Day | -2.4% | 2.2% | 1.5% |
| 30 Day | -1.4% | 1.0% | 1.4% |
| 90 Day | 12.8% | 8.7% | 8.7% |
| 1 Year | 13.2%12.9% | 23.0%22.1% | 22.7%20.1% |
| 3 Year | 115.2%112.8% | 84.6%79.4% | 50.1%40.5% |
| 5 Year | 265.8%257.1% | 117.1%94.4% | 73.1%54.1% |
Price Volatility Vs. Market
How volatile is Mesa Laboratories's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Here's Why Mesa Laboratories's (NASDAQ:MLAB) Statutory Earnings Are Arguably Too Conservative3 months ago | Simply Wall St
A Close Look At Mesa Laboratories, Inc.’s (NASDAQ:MLAB) 13% ROCE4 months ago | Simply Wall St
Did You Miss Mesa Laboratories's (NASDAQ:MLAB) Whopping 322% Share Price Gain?Valuation
Is Mesa Laboratories undervalued compared to its fair value and its price relative to the market?
240.24x
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: MLAB ($261.84) is trading above our estimate of fair value ($183.18)
Significantly Below Fair Value: MLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: MLAB is poor value based on its PE Ratio (240.2x) compared to the Medical Equipment industry average (47.1x).
PE vs Market: MLAB is poor value based on its PE Ratio (240.2x) compared to the US market (18.4x).
Price to Earnings Growth Ratio
PEG Ratio: MLAB is poor value based on its PEG Ratio (5.7x)
Price to Book Ratio
PB vs Industry: MLAB is overvalued based on its PB Ratio (4.9x) compared to the US Medical Equipment industry average (4x).
Next Steps
Future Growth
How is Mesa Laboratories forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
42.0%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MLAB's forecast earnings growth (42% per year) is above the savings rate (1.7%).
Earnings vs Market: MLAB's earnings (42% per year) are forecast to grow faster than the US market (14.5% per year).
High Growth Earnings: earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MLAB's revenue (16.2% per year) is forecast to grow faster than the US market (7.6% per year).
High Growth Revenue: MLAB's revenue (16.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MLAB's Return on Equity is forecast to be low in 3 years time (11.9%).
Next Steps
Past Performance
How has Mesa Laboratories performed over the past 5 years?
-16.7%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MLAB has a large one-off loss of $7.7M impacting its December 31 2019 financial results.
Growing Profit Margin: MLAB's current net profit margins (4%) are lower than last year (10%).
Past Earnings Growth Analysis
Earnings Trend: MLAB's earnings have declined by -16.7% per year over the past 5 years.
Accelerating Growth: MLAB's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: MLAB had negative earnings growth (-57.1%) over the past year, making it difficult to compare to the Medical Equipment industry average (7.1%).
Return on Equity
High ROE: MLAB's Return on Equity (1.9%) is considered low.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Mesa Laboratories's financial position?
Financial Position Analysis
Short Term Liabilities: MLAB's short term assets ($120.7M) exceed its short term liabilities ($25.2M).
Long Term Liabilities: MLAB's short term assets ($120.7M) do not cover its long term liabilities ($164.1M).
Debt to Equity History and Analysis
Debt Level: MLAB's debt to equity ratio (59.3%) is considered high.
Reducing Debt: MLAB's debt to equity ratio has increased from 39% to 59.3% over the past 5 years.
Debt Coverage: MLAB's debt is well covered by operating cash flow (20.4%).
Interest Coverage: MLAB's interest payments on its debt are well covered by EBIT (7.8x coverage).
Balance Sheet
Inventory Level: MLAB has a low level of unsold assets or inventory.
Debt Coverage by Assets: MLAB's debt is not covered by short term assets (assets are 0.9x debt).
Next Steps
Dividend
What is Mesa Laboratories's current dividend yield, its reliability and sustainability?
0.24%
Current Dividend Yield
Upcoming Dividend Payment
Purchase Mesa Laboratories before the 'Buy Limit' to receive their next dividend payment.
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: MLAB's dividend (0.24%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.44%).
High Dividend: MLAB's dividend (0.24%) is low compared to the top 25% of dividend payers in the US market (3.69%).
Stability and Growth of Payments
Stable Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: MLAB is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MLAB is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.2yrs
Average management tenure
CEO
Gary Owens (51yo)
2.4yrs
Tenure
US$3,270,589
Compensation
Mr. Gary M. Owens has been Chief Executive Officer, President and Director of Mesa Laboratories, Inc. since September 1, 2017. Mr. Owens joined as Chief Operating Officer in March 2017. Mr. Owens served as ...
CEO Compensation Analysis
Compensation vs Market: Gary's total compensation ($USD3.27M) is above average for companies of similar size in the US market ($USD2.47M).
Compensation vs Earnings: Gary's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.4yrs | US$3.27m | 0.36% $4.1m | |
| CFO, Chief Accounting Officer | 7.3yrs | US$1.03m | 0.080% $916.4k | |
| Senior Vice President of Commercial Operations | 2.3yrs | US$866.64k | 0.033% $382.8k | |
| General Counsel | 6.1yrs | no data | no data | |
| Vice President of Corporate Development & Strategy | 4yrs | no data | no data | |
| Senior Vice President of Operations | 0yrs | US$281.45k | no data | |
| Senior Vice President of Operations | 0yrs | US$280.56k | no data | |
| Senior Vice President of Continuous Improvement | 2.1yrs | no data | 0.0081% $92.9k |
3.2yrs
Average Tenure
51yo
Average Age
Experienced Management: MLAB's management team is considered experienced (3.2 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 2.4yrs | US$3.27m | 0.36% $4.1m | |
| Independent Director | 9.3yrs | US$131.33k | 0.064% $727.9k | |
| Independent Director | 11yrs | US$132.33k | 0.82% $9.4m | |
| Independent Director | 1.1yrs | US$69.64k | 0.0063% $72.0k | |
| Chairman of the Board | 2.4yrs | US$146.83k | 1.63% $18.7m | |
| Independent Director | 13.8yrs | US$124.83k | 0.82% $9.3m | |
| Independent Director | 4.8yrs | US$124.83k | 1.72% $19.7m | |
| Independent Director | 0.9yrs | US$54.25k | 0.0048% $54.7k |
3.6yrs
Average Tenure
56.5yo
Average Age
Experienced Board: MLAB's board of directors are considered experienced (3.6 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MLAB insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.
Top Shareholders
Company Information
Mesa Laboratories, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Mesa Laboratories, Inc.
- Ticker: MLAB
- Exchange: NasdaqGS
- Founded: 1982
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$1.144b
- Shares outstanding: 4.37m
- Website: https://www.mesalabs.com
Number of Employees
Location
- Mesa Laboratories, Inc.
- 12100 West Sixth Avenue
- Lakewood
- Colorado
- 80228
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MLAB | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Feb 1984 |
Biography
Mesa Laboratories, Inc. designs, manufactures, and markets quality control instruments and disposable products in Europe, Africa, Asia, South America, Australia, Canada, and Central America. The company’s Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness. This segment’s products are used in healthcare, pharmaceutical, medical device, food and beverage, industrial hygiene, and environmental air sampling industries. Its Sterilization and Disinfection Control segment manufactures and markets biological indicators comprising spore strips, self-contained products, and culture media, as well as process challenge devices; and testing services. This segment also provides chemical indicators that are used to assess the effectiveness of sterilization processes; and cleaning indicators, which are used to assess the effectiveness of cleaning processes. The company’s Cold Chain Monitoring segment offers systems, which are used to monitor various environmental parameters, such as temperature, humidity, and differential pressure for use in hospitals, pharmaceutical and medical device manufacturers, blood banks, pharmacies, and laboratory environments; parameter monitoring services for products in a cold chain; and consulting services. Its Cold Chain Packaging segment offers thermal packaging products, such as coolers, boxes, insulation materials, and phase-change products to control temperature during transport. Mesa Laboratories, Inc. was founded in 1982 and is headquartered in Lakewood, Colorado.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/02/16 23:42 |
| End of Day Share Price | 2020/02/14 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/03/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.